Literature DB >> 16837598

Endogenous alpha-synuclein is induced by valproic acid through histone deacetylase inhibition and participates in neuroprotection against glutamate-induced excitotoxicity.

Yan Leng1, De-Maw Chuang.   

Abstract

Emerging evidence suggests that alpha-synuclein (alpha-syn), which is traditionally thought to have a pathophysiological role in neurodegenerative diseases, can have neuroprotective effects. This study aimed to investigate whether endogenous alpha-syn in neurons can be induced by valproic acid (VPA), a mood-stabilizer, anticonvulsant and histone deacetylase (HDAC) inhibitor, and if so, whether the alpha-syn induction is neuroprotective. VPA treatment of rat cerebellar granule cells caused a robust dose- and time-dependent increase in levels of alpha-syn protein and mRNA and in the intensity of alpha-syn immunostaining. Knockdown of VPA-induced alpha-syn overexpression with alpha-syn antisense oligonucleotides or siRNA completely blocked VPA-induced neuroprotection. alpha-Syn knockdown also exacerbated glutamate neurotoxicity, stimulated the expression of the proapoptotic gene ubiquitin-conjugating enzyme E2N, and downregulated the expression of the anti-apoptotic gene Bcl-2. Induction of alpha-syn by VPA was associated with inhibition of HDAC activity, resulting in hyperacetylation of histone H3 in the alpha-syn promoter and a marked increase in alpha-syn promoter activity. Moreover, VPA-induced alpha-syn induction and neuroprotection were mimicked by HDAC inhibitors sodium 4-phenylbutyrate and trichostatin A (TSA). alpha-syn was also induced by VPA in rat cerebral cortical neurons. Additionally, treatment of rats with VPA, sodium butyrate, or TSA markedly increased alpha-syn protein levels in the cortex and cerebellum. Together, our results demonstrate for the first time that VPA induces alpha-syn in neurons through inhibition of HDAC and that this alpha-syn induction is critically involved in neuroprotection against glutamate excitotoxicity. Clinically, VPA may represent a suitable treatment for excitotoxicity-related neurodegenerative diseases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16837598      PMCID: PMC6674182          DOI: 10.1523/JNEUROSCI.0096-06.2006

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  74 in total

1.  Enhancement of Autophagy by Histone Deacetylase Inhibitor Trichostatin A Ameliorates Neuronal Apoptosis After Subarachnoid Hemorrhage in Rats.

Authors:  Anwen Shao; Zhen Wang; Haijian Wu; Xiao Dong; Yong Li; Sheng Tu; Junjia Tang; Mingfei Zhao; Jianmin Zhang; Yuan Hong
Journal:  Mol Neurobiol       Date:  2014-11-18       Impact factor: 5.590

2.  Long-term administration of the histone deacetylase inhibitor vorinostat attenuates renal injury in experimental diabetes through an endothelial nitric oxide synthase-dependent mechanism.

Authors:  Andrew Advani; Qingling Huang; Kerri Thai; Suzanne L Advani; Kathryn E White; Darren J Kelly; Darren A Yuen; Kim A Connelly; Philip A Marsden; Richard E Gilbert
Journal:  Am J Pathol       Date:  2011-05       Impact factor: 4.307

3.  Alpha-synuclein loss in spinal muscular atrophy.

Authors:  Gyula Acsadi; Xingli Li; Kelley J Murphy; Kathryn J Swoboda; Graham C Parker
Journal:  J Mol Neurosci       Date:  2010-07-17       Impact factor: 3.444

4.  Antagonizing Neuronal Toll-like Receptor 2 Prevents Synucleinopathy by Activating Autophagy.

Authors:  Changyoun Kim; Edward Rockenstein; Brian Spencer; Hyung-Koo Kim; Anthony Adame; Margarita Trejo; Klodjan Stafa; He-Jin Lee; Seung-Jae Lee; Eliezer Masliah
Journal:  Cell Rep       Date:  2015-10-17       Impact factor: 9.423

Review 5.  Neuroprotection as a Potential Therapeutic Perspective in Neurodegenerative Diseases: Focus on Antiepileptic Drugs.

Authors:  D Caccamo; L R Pisani; P Mazzocchetti; R Ientile; P Calabresi; F Pisani; C Costa
Journal:  Neurochem Res       Date:  2015-12-31       Impact factor: 3.996

6.  Effect of α-synuclein on amyloid β-induced toxicity: relevance to Lewy body variant of Alzheimer disease.

Authors:  Rosa Resende; Sueli C F Marques; Elisabete Ferreiro; Isaura Simões; Catarina R Oliveira; Cláudia M F Pereira
Journal:  Neurochem Res       Date:  2013-02-07       Impact factor: 3.996

7.  β2-Adrenoreceptor is a regulator of the α-synuclein gene driving risk of Parkinson's disease.

Authors:  Shuchi Mittal; Kjetil Bjørnevik; Doo Soon Im; Adrian Flierl; Xianjun Dong; Joseph J Locascio; Kristine M Abo; Elizabeth Long; Ming Jin; Bing Xu; Yang K Xiang; Jean-Christophe Rochet; Anders Engeland; Patrizia Rizzu; Peter Heutink; Tim Bartels; Dennis J Selkoe; Barbara J Caldarone; Marcie A Glicksman; Vikram Khurana; Birgitt Schüle; David S Park; Trond Riise; Clemens R Scherzer
Journal:  Science       Date:  2017-09-01       Impact factor: 47.728

Review 8.  Glutamate and neurotrophic factors in neuronal plasticity and disease.

Authors:  Mark P Mattson
Journal:  Ann N Y Acad Sci       Date:  2008-11       Impact factor: 5.691

9.  Behavioral and histopathological consequences of paraquat intoxication in mice: effects of alpha-synuclein over-expression.

Authors:  P O Fernagut; C B Hutson; S M Fleming; N A Tetreaut; J Salcedo; E Masliah; M F Chesselet
Journal:  Synapse       Date:  2007-12       Impact factor: 2.562

10.  Valproic acid: an anticonvulsant drug with potent antinociceptive and anti-inflammatory properties.

Authors:  José Christian Machado Ximenes; Danilo de Oliveira Gonçalves; Rafaelly Maria Pinheiro Siqueira; Kelly Rose Tavares Neves; Gilberto Santos Cerqueira; Alyne Oliveira Correia; Francisco Hélder Cavalcante Félix; Luzia Kalyne Almeida Moreira Leal; Gerly Anne de Castro Brito; Maria da Graça Naffah-Mazzacorati; Glauce Socorro de Barros Viana
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-04-14       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.